Coronavirus Update: Clover Begins Twin Track Trials With GSK And Dynavax
Plus: Are UK's New Takeover Laws Prompted By AstraZeneca Fears?
Clover enters the clinical trial stage in race to develop a vaccine, while the UK moves to protect a range of key industries from foreign takeover, including vaccines manufacturers. Meanwhile, confirmed cases in Beijing continue to rise.
You may also be interested in...
Plus: the World Health Organization has commissioned an independent panel to look at pandemic responses, while the emergence of an unknown pneumonia in Kazakstan is causing concern.
Moderna's vaccine has shown encouraging early results in younger adults, but over-55s and over-70s cohorts represent a bigger safety and efficacy hurdle.
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.